ASND vs IVA
Ascendis Pharma A/S and Inventiva S.a., side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ASND | IVA |
|---|---|---|
| Revenue | €720.1M | €9.2M |
| Net income | €-228.0M | €-184.2M |
| Gross margin | 86.8% | — |
| Net margin | −31.7% | −2002.7% |
| Return on equity | — | — |
| Diluted EPS | −€3.76 | −€3.08 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-469.8M | — |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 1.04× | 0.92× |
| Revenue CAGR 5y | 153.0% | 5.6% |
| Profit CAGR 5y | — | — |
ASND bills 78.3× the revenue of IVA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | ASND | IVA |
|---|---|---|
| FY2024 | €363.6M | €9.2M |
| FY2023 | €266.7M | €17.5M |
| FY2022 | €51.2M | €12.2M |
| FY2021 | €7.8M | €4.2M |
| FY2020 | €7.0M | €372,000 |
| FY2019 | €13.4M | €7.0M |
| FY2018 | €10.6M | €3.2M |
Net income by year
Bottom line
| Fiscal year | ASND | IVA |
|---|---|---|
| FY2024 | €-378.1M | €-184.2M |
| FY2023 | €-481.4M | €-110.4M |
| FY2022 | €-583.2M | €-54.3M |
| FY2021 | €-383.6M | €-49.6M |
| FY2020 | €-419.0M | €-33.6M |
| FY2019 | €-218.0M | €-30.2M |
| FY2018 | €-130.1M | €-33.0M |
Advertisement
AdSense · Rectangle 336×280